Merger and acquisition activity in the peptide industry has reached high levels. Large pharmaceutical companies are acquiring peptide capabilities to compete in the booming GLP-1 market and position for the next wave of peptide therapeutics.
This article analyzes the M&A landscape, strategic drivers, and what to expect for the rest of 2026.
- Peptide-related M&A deals totaled $28 billion in 2025, up 60% from 2024
- Manufacturing capacity is the most sought-after acquisition target
- Oral peptide delivery platforms command premium valuations
- Big pharma is acquiring to build or expand peptide portfolios
- Smaller deals for AI-peptide platforms are increasing rapidly
Deal Volume and Value
The peptide M&A market has exploded alongside the broader peptide therapeutics market.
| Year | Number of Deals | Total Deal Value | Largest Single Deal |
|---|---|---|---|
| 2022 | 22 | $8.5 billion | $3.2 billion |
| 2023 | 31 | $12.8 billion | $4.1 billion |
| 2024 | 38 | $17.5 billion | $5.8 billion |
| 2025 | 45 | $28.0 billion | $8.5 billion |
| 2026 YTD | 14 | $9.2 billion | $4.3 billion |
The sharp increase in deal value reflects both the growing number of transactions and rising valuations for peptide assets.
The combined value of peptide M&A deals in 2025 exceeded the total market capitalization of the entire peptide CDMO industry just three years earlier. The speed of market transformation has surprised even bullish industry observers.
Strategic Drivers
Building GLP-1 Portfolios
The success of semaglutide and tirzepatide has demonstrated the enormous market potential of GLP-1 drugs. Companies without GLP-1 programs are acquiring them to compete.
Acquisitions target companies with next-generation GLP-1 molecules (oral formulations, multi-agonists, longer-acting versions) that could differentiate from current market leaders.
Securing Manufacturing Capacity
Peptide manufacturing capacity is the single biggest bottleneck limiting market growth. Companies are acquiring CDMOs to secure dedicated manufacturing capacity rather than competing for scarce contract slots.
| Acquirer Type | Target | Strategic Rationale |
|---|---|---|
| Big Pharma | Peptide CDMOs | Secure supply for GLP-1 programs |
| CDMOs | Smaller CDMOs | Consolidate and expand capacity |
| Specialty Pharma | Peptide startups with facilities | Acquire both pipeline and capacity |
Accessing Enabling Technologies
Technology platforms are highly sought-after acquisition targets:
Oral delivery: Companies with oral peptide delivery technology command valuations of 10 to 20 times revenue due to the potential of making injectable drugs available as pills.
AI-driven design: AI platforms that accelerate peptide drug discovery are attracting both pharma and tech acquirers. The combination of AI capability with peptide domain expertise is rare and valuable.
Novel chemistry: Companies with proprietary peptide modification technologies (stapling, cyclization, conjugation) provide acquiring companies with differentiated chemistry platforms.
Expanding Therapeutic Focus
Companies with strong positions in one therapeutic area are acquiring into others. For example, a company with GLP-1 expertise might acquire a peptide oncology startup to diversify its pipeline.
Oral peptide delivery platforms commanded acquisition premiums of 10x to 20x revenue in 2025, making them the highest valued assets in the entire peptide M&A landscape.
Notable Recent Deals
Manufacturing Acquisitions
Several major manufacturing deals have shaped the industry:
Large pharma companies have acquired or taken major stakes in peptide CDMOs to ensure supply chain security. These deals typically include long-term supply commitments alongside the equity investment.
Technology Platform Acquisitions
Oral peptide delivery companies have been particularly active targets. The premium paid for oral delivery technology reflects the enormous market opportunity of converting injectable GLP-1 drugs to oral formulations.
AI-peptide platform companies have attracted acquisition interest from both pharma and tech companies. The convergence of artificial intelligence and drug discovery creates a new category of acquisition target.
Pipeline Acquisitions
Traditional pipeline deals, where a larger company acquires a smaller one for its drug candidates, remain common. Peptide programs in Phase II or later clinical development command the highest premiums.
Dr. Richard Hayes, Biotech M&A Advisor put it plainly: "The M&A market for peptide companies is white-hot. We are seeing multiple bidders for quality assets and deal timelines compressing from months to weeks. Companies with differentiated technology and strong teams are in a seller's market."
If your peptide business has proprietary manufacturing processes or delivery technology, get a formal valuation now. Acquirers are paying historic premiums for these capabilities, and the window of peak valuations may narrow as more capacity comes online in late 2027.
Valuation Trends
Premiums Are Rising
Acquisition premiums (the amount paid above the target's market value) for peptide companies have increased significantly:
| Stage | Average Premium (2023) | Average Premium (2025) |
|---|---|---|
| Preclinical | 80% to 120% | 120% to 200% |
| Phase I/II | 100% to 150% | 150% to 250% |
| Phase III | 50% to 80% | 80% to 120% |
| Commercial | 30% to 50% | 50% to 80% |
Revenue Multiples
For peptide companies with commercial products, revenue multiples have also expanded:
| Company Type | Revenue Multiple (2023) | Revenue Multiple (2025) |
|---|---|---|
| Pure-play peptide therapeutics | 8x to 12x | 12x to 20x |
| Peptide CDMO | 4x to 6x | 6x to 10x |
| AI-peptide platform | 15x to 25x (on committed revenue) | 20x to 40x |
Private Company Valuations
For private peptide companies, Series B valuations have roughly doubled since 2023. Companies with clinical-stage assets are achieving pre-money valuations of $200 million to $500 million at Series B.
Impact on the Industry
Talent Migration
M&A activity creates talent migration as acquired teams join larger organizations. Some scientists thrive in larger companies with more resources. Others leave for new startups, taking their expertise into the next generation of peptide companies.
Innovation Effects
Industry consolidation can both help and hinder innovation. Larger companies bring more resources to peptide development, but they may also slow down the nimble innovation that characterized smaller companies.
The healthiest market dynamic is one where M&A recycles talent and capital into new ventures even as it consolidates mature businesses.
Pricing Implications
As the peptide industry consolidates, pricing power may shift. Fewer CDMO competitors could lead to higher manufacturing costs. Conversely, larger companies may achieve economies of scale that reduce costs.
What to Expect in 2026
Continued High Activity
M&A activity in the peptide space is expected to remain strong through 2026. Several large pharma companies have publicly stated their intent to build or expand peptide portfolios.
Manufacturing Focus
Manufacturing acquisitions will continue as demand for peptide drug production outpaces capacity. Companies that built manufacturing infrastructure early are now valuable acquisition targets.
Cross-Border Deals
Expect more cross-border transactions, particularly involving Chinese and Korean peptide companies entering partnerships or acquisitions with Western firms.
SPAC and Reverse Mergers
Some smaller peptide companies may use SPAC mergers or reverse mergers as alternative paths to public markets, particularly if traditional IPO windows narrow.
Peptide M&A is being driven by capacity scarcity and platform value, not just pipeline assets, so businesses with manufacturing infrastructure or enabling technology hold outsized leverage in today's market.
FAQ
What makes a peptide company an attractive acquisition target?
The most attractive targets have differentiated technology (unique chemistry, delivery platform, or AI capabilities), clinical-stage or commercial products, strong IP protection, and a talented team. Manufacturing capacity is also highly valued in the current market.
How long does a typical peptide M&A deal take?
From initial discussions to deal close, typical timelines range from 3 to 9 months. Competitive situations with multiple bidders may close faster. Regulatory reviews (antitrust, CFIUS for cross-border deals) can extend timelines.
Should my peptide startup prepare for potential acquisition?
Yes. Even if you plan to remain independent, maintaining clean corporate records, strong IP documentation, and organized data rooms makes your company more valuable and ready for any opportunity. Most successful biotech exits involve some M&A preparation.
What happens to employees after a peptide company is acquired?
It varies. Key scientists and leadership often receive retention packages to stay through a transition period (typically 1 to 2 years). Some roles may be eliminated due to overlap. Many employees at acquired startups find the transition to a larger organization challenging and eventually move on.
Are peptide CDMO valuations sustainable at current levels?
Current valuations reflect the extreme supply-demand imbalance in peptide manufacturing. As new capacity comes online (expected 2027 to 2028), valuations may moderate. However, the overall market growth should support continued strong valuations for well-positioned CDMOs.
Topics
Amanda Foster
Peptide Industry Analyst
MS, Health Economics | 8 years in peptide market research
Tracks workforce trends, compensation data, and market dynamics across the peptide industry. Produces quarterly salary benchmarks and employer-of-record analysis cited by clinic operators nationwide.
Reviewed by Amanda Foster, MS, April 2026